Darryl Patrick

Dr. Darryl Patrick has been in Pharmaceutical Research and Development specializing in Nonclinical Development for over 30 years. He began his career at Merck Research Laboratories serving in numerous roles over 20 years ultimately serving as Vice President/Head, Worldwide Safety Assessment responsible for all nonclinical aspects for potential drug development candidates, including toxicologic evaluation, defining preclinical drug development candidate plans, interacting with drug development teams, preparing regulatory submissions including INDs/NDAs, and dialoguing with Regulatory Agencies around the World, including at Scientific Advisory Committee Meetings with the FDA and Scientific Advice Meetings within the EU. Dr. Patrick has also served on Research and Development Management teams where he was responsible for the overall strategic plans for R&D including defining potential molecular research targets for therapeutic development, selecting potential drug development candidates, defining risk /benefit criteria for drug development candidates, and the oversight of drug development programs thru to approval. He moved to Vertex Pharmaceuticals in 2004 as Vice President, Nonclinical Development. In this role, he oversaw the establishment of disciplines in Toxicology and ADME to support the early development efforts at Vertex. Dr. Patrick served on Management oversight committees. Subsequently, he was promoted to Vice President, Exploratory Development responsible for all nonclinical development activities and Clinical Pharmacology directing programs through to proof of concept. While at Vertex, Dr. Patrick was a member of the management team responsible for the first NCE developed within the Company. For the past several years since retiring from Vertex Pharmaceuticals, Dr. Patrick has engaged in private consulting for biotechnology and life sciences companies engaged in early drug development efforts focused on novel therapeutic targets. He has also served on Scientific Advisory Boards providing guidance on nonclinical development activities and interacted with regulatory agencies around the world as a nonclinical expert.